Rab7A Is Required for Efficient Production of Infectious HIV-1

por Caillet, Marina, Janvier, Katy, Pelchen–Matthews, Annegret, Delcroix-Genête, Delphine, Camus, Grégory, Marsh, Mark, Berlioz-Torrent, Clarisse
Publicado 2011

Lipid Droplet-Binding Protein TIP47 Regulates Hepatitis C Virus RNA Replication through Interaction with the Viral NS5A Protein

por Vogt, Dorothee A., Camus, Grégory, Herker, Eva, Webster, Brian R., Tsou, Chia-Lin, Greene, Warner C., Yen, Tien-Sze Benedict, Ott, Melanie
Publicado 2013

Extended Remdesivir Infusion for Persistent Coronavirus Disease 2019 Infection

por Martinez, Mario A, Chen, Ting-Yi, Choi, Hosoon, Hwang, Munok, Navarathna, Dhammika, Hao, Linhue, Gale, Michael, Camus, Gregory, Ramirez, Hector E, Jinadatha, Chetan
Publicado 2022

Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)

por Hedskog, Charlotte, Rodriguez, Lauren, Roychoudhury, Pavitra, Huang, Meei-Li, Jerome, Keith R, Hao, Linhui, Ireton, Renee C, Li, Jiani, Perry, Jason K, Han, Dong, Camus, Gregory, Greninger, Alexander L, Gale, Michael, Porter, Danielle P
Publicado 2023

Prognostic value of severe acute respiratory syndrome coronavirus‐2 viral load and antibodies in patients hospitalized with COVID‐19

por Bauer, Rebecca N., Teterina, Anastasia, Shivram, Haridha, McBride, Jacqueline, Rosenberger, Carrie M., Cai, Fang, Bao, Min, Tsai, Larry, Gordon, Oliver, Lee, Ivan T., Wallin, Jeffrey J., Porter, Danielle, Juneja, Kavita, Camus, Gregory, Rosas, Ivan O., Wildum, Steffen
Publicado 2023

1149. Resistance Analyses of Patient Viral Samples from the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)

por Hedskog, Charlotte, Rodriguez, Lauren, Beigel, John H, Dempsey, Walla, Greninger, Alexander L, Roychoudhury, Pavitra, Huang, Meei-Li, Jerome, Keith R, Hao, Linhui, Ireton, Renee, Gale, Michael, Li, Jiani, Perry, Jason, Han, Dong, Camus, Gregory, Porter, Danielle P
Publicado 2022

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants

por Pitts, Jared, Li, Jiani, Perry, Jason K., Du Pont, Venice, Riola, Nicholas, Rodriguez, Lauren, Lu, Xianghan, Kurhade, Chaitanya, Xie, Xuping, Camus, Gregory, Manhas, Savrina, Martin, Ross, Shi, Pei-Yong, Cihlar, Tomas, Porter, Danielle P., Mo, Hongmei, Maiorova, Evguenia, Bilello, John P.
Publicado 2022

Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India

por Sood, Ajit, Duseja, Ajay, Kabrawala, Mayank, Amrose, Pradeep, Goswami, Bhadadev, Chowdhury, Abhijit, Sarin, Shiv Kumar, Koshy, Abraham, Hyland, Robert H., Lu, Sophia, Camus, Gregory, Stamm, Luisa M., Brainard, Diana M., Subramanian, G. Mani, Prasad, Madhura, Bhatia, Shobna, Shah, Samir R., Kapoor, Dharmesh, Shalimar, Saraswat, Vivek
Publicado 2019

3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China

por Hou, Jinlin, Ning, Qin, Duan, Zhongping, Chen, You, Xie, Qing, Wang, Fu-Sheng, Zhang, Lunli, Wu, Shanming, Tang, Hong, Li, Jun, Lin, Feng, Yang, Yongfeng, Gong, Guozhong, Flaherty, John F., Gaggar, Anuj, Mo, Shuyuan, Cheng, Cong, Camus, Gregory, Chen, Chengwei, Huang, Yan, Jia, Jidong, Zhang, Mingxiang
Publicado 2021

Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study

por Wei, Lai, Xie, Qing, Hou, Jin Lin, Tang, Hong, Ning, Qin, Cheng, Jun, Nan, Yuemin, Zhang, Lunli, Li, Jun, Jiang, Jianning, McNabb, Brian, Zhang, Fangqiu, Camus, Gregory, Mo, Hongmei, Osinusi, Anu, Brainard, Diana M., Gong, Guozhong, Mou, Zhuangbo, Wu, Shanming, Wang, Guiqiang, Hu, Peng, Gao, Yanhang, Jia, Jidong, Duan, Zhongping
Publicado 2018

LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial

por Hill, Joshua A, Paredes, Roger, Vaca, Carlos, Mera, Jorge, Webb, Brandon J, Perez, Gilberto, Oguchi, Godson, Ryan, Pablo, Gerstoft, Jan, Brown, Michael, Schiffer, Joshua, Brown, Samuel, Katz, Morgan, Ginde, Adit A, Camus, Gregory, Porter, Danielle P, Hyland, Robert H, Chen, Shuguang, Juneja, Kavita, Osinusi, Anu, Duff, Frank, Gottlieb, Robert L
Publicado 2021

Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals

por Izumi, Namiki, Takehara, Tetsuo, Chayama, Kazuaki, Yatsuhashi, Hiroshi, Takaguchi, Koichi, Ide, Tatsuya, Kurosaki, Masayuki, Ueno, Yoshiyuki, Toyoda, Hidenori, Kakizaki, Satoru, Tanaka, Yasuhito, Kawakami, Yoshiiku, Enomoto, Hirayuki, Ikeda, Fusao, Jiang, Deyuan, De-Oertel, Shampa, McNabb, Brian L., Camus, Gregory, Stamm, Luisa M., Brainard, Diana M., McHutchison, John G., Mochida, Satoshi, Mizokami, Masashi
Publicado 2018

Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment

por Liu, Chun Jen, Sheen, I Shyan, Chen, Chi Yi, Chuang, Wan Long, Wang, Horng Yuan, Tseng, Kuo Chih, Chang, Ting Tsung, Yang, Jenny, Massetto, Benedetta, Suri, Vithika, Camus, Gregory, Jiang, Deyuan, Zhang, Fangqiu, Gaggar, Anuj, Hu, Tsung Hui, Hsu, Yu Chun, Lo, Gin Ho, Chu, Chi Jen, Chen, Jyh Jou, Peng, Cheng Yuan, Chien, Rong Nan, Chen, Pei Jer
Publicado 2021

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

por Gottlieb, Robert L., Vaca, Carlos E., Paredes, Roger, Mera, Jorge, Webb, Brandon J., Perez, Gilberto, Oguchi, Godson, Ryan, Pablo, Nielsen, Bibi U., Brown, Michael, Hidalgo, Ausberto, Sachdeva, Yessica, Mittal, Shilpi, Osiyemi, Olayemi, Skarbinski, Jacek, Juneja, Kavita, Hyland, Robert H., Osinusi, Anu, Chen, Shuguang, Camus, Gregory, Abdelghany, Mazin, Davies, Santosh, Behenna-Renton, Nicole, Duff, Frank, Marty, Francisco M., Katz, Morgan J., Ginde, Adit A., Brown, Samuel M., Schiffer, Joshua T., Hill, Joshua A.
Publicado 2021